

CLAIMS

1. A method for increasing bone density in a subject, the method comprising: parenterally implanting in said subject a sustained release dosage form, said sustained release dosage form comprising a drug delivery device and a bone density-modulating drug, and administering said drug from said dosage form into said subject, for a period of at least 24 hours, in an dose sufficient to cause a measurable increase in bone density.
2. The method of claim 1, wherein said drug is a bisphosphonate.
3. The method of claim 2, wherein said drug delivery device is selected from the group consisting of: a pump, a bioerodable implant, and a depot.
4. The method of claim 3, wherein said bisphosphonate is administered at a rate of from about 0.1 μg per hour to 200 μg per hour for a period of at least a week
5. The method of claim 3, wherein said dosage form comprises a depot.
6. The method of claim 5, wherein said depot comprises a non-polymeric high viscosity material.
7. The method of claim 6, wherein said high viscosity material comprises sucrose acetate isobutyrate.
8. The method of claim 3, wherein said dosage form comprises a biodegradable implant.
9. The method of claim 8 wherein said biodegradable implant comprises a polymer, and wherein said polymer is selected from the group consisting of: poly(DL lactide-co-glycolide), polycaprolactone, polyglycolide, and combinations thereof.
10. The method of claim 3, wherein said drug delivery device comprises a microsphere formulation, and wherein said microsphere formulation comprises a polymer selected from the group of poly(DL-lactide-co-glycolide), polycaprolactone, polyglycolide, and combinations thereof.
11. The method of claim 3, wherein said dosage form comprises a pump.
12. A method for increasing bone density in a subject, the method comprising: implanting in said subject a sustained release dosage form, said sustained release dosage form

comprising a non-polymeric depot, and a bisphosphonate, and administering said bisphosphonate from said non-polymeric depot into said subject, for a period of at least a week, in an dose sufficient to cause a measurable increase in bone density.

13. An implantable dosage form comprising a drug delivery device and a bisphosphonate, wherein said drug delivery device is selected from the group consisting of: a bioerodable implant, a depot, and a microsphere formulation.

14. The implantable dosage form of claim 13 wherein the drug delivery device comprises a non-polymeric high viscosity material.